Company | Date | Price Target | Rating | Analyst |
---|---|---|---|---|
7/22/2024 | $12.00 → $18.00 | Underperform → Neutral | BofA Securities | |
7/17/2024 | $27.00 | Outperform → Neutral | Robert W. Baird | |
7/10/2024 | $20.00 | Hold → Buy | Argus | |
6/24/2024 | $12.00 | Sell | Goldman | |
3/19/2024 | $13.00 | Neutral | Guggenheim | |
3/8/2024 | $14.00 | Underweight → Neutral | JP Morgan | |
3/8/2024 | $22.00 | Equal Weight | Barclays | |
2/12/2024 | $12.00 → $19.00 | Neutral → Overweight | Piper Sandler |
4 - Bioventus Inc. (0001665988) (Issuer)
4 - Clene Inc. (0001822791) (Issuer)
SCHEDULE 13G - TaskUs, Inc. (0001829864) (Subject)
8-K - Clene Inc. (0001822791) (Filer)
6-K - Alibaba Group Holding Ltd (0001577552) (Filer)
GREEN BAY, Wis., June 28, 2024 /PRNewswire/ -- Associated Banc-Corp (NYSE:ASB) ("Associated") announced today that Tammy C. Stadler, 58, Executive Vice President, Corporate Controller and Chief Accounting Officer, will retire from those positions effective July 15, 2024. Stadler will remain with Associated in a consultative capacity until September 1, 2024, to assure a successful transition of her duties. Stadler will be succeeded as Corporate Controller and Chief Accounting Officer by Ryan Beld, 35. Beld, currently the Assistant Controller, joined Associated in 2020. Prior to joining Associated, Beld was a senior financial analyst with Northwestern Mutual. Beld is a CPA and was employed by
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the appointment of Matthew Shields as Executive Vice President of Teva Global Operations (TGO), the Company's manufacturing and supply division, effective June 3, 2024. Mr. Shields succeeds Eric Drapé, who is leaving after 11 years with the Company, including more than four years as Executive Vice President, Global Operations. Mr. Shields will be a member of Teva's Executive Leadership Team and report directly to President and CEO Richard Francis. He will be based in Teva's U.S. headquarters in Parsippany, NJ. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/2
Andrew Makrides Retiring Following More Than 40 Years of Service as Chairman of the Board of Directors; Stavros Vizirgianakis Appointed to Succeed Mr. Makrides as Chairman Apyx Medical Corporation (NASDAQ:APYX) ("Apyx Medical"; the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced the retirement of Andrew Makrides as Chairman of the Board, after serving the Company in this position since 1982. The Board of Directors has appointed Stavros Vizirgianakis Chairman of the Board, effective as of May 7, 2024. "On behalf of the entire organization, I would like to express our gratitude to Andrew for his lead
The People’s Bank of China (PBOC) has executed an unscheduled lending operation at significantly lower rates, indicating a potential increase in monetary stimulus to support the economy. What Happened: The PBOC conducted a medium-term lending facility (MLF) operation, issuing 200 billion yuan ($27.5 billion) in one-year loans at a rate of 2.30%, a 20 basis point decrease from the previous MLF loan, Reuters reported. This move follows the bank’s decision to cut several benchmark lending rates just days after a key leadership meeting that outlined major reforms. The central bank also injected 235.1 billion yuan into the market through seven-day reverse repos at 1.70%. This cash injection
Enrollment acceleration drives earlier-than-anticipated data availability for this potentially best-in-class IBD treatment Topline results for both UC and CD now anticipated in Q4 2024 Teva and Sanofi are collaborating to co-develop and co-commercialize duvakitug (anti-TL1A) for moderate-to-severe ulcerative colitis (UC) and Crohn's disease (CD) patients
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner. Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels. Below are some instances of options activity happening in the Consumer Discretionary sector: Symbol PUT/CALL Trade Type Sentiment Exp. Date Strike Price Total Trade Price Open Interest Volume BABA CALL TRADE BULLISH 08/02/24 $79.00 $27.0K 2.4K 1.7K SBUX CALL TRADE B
BofA Securities upgraded TaskUs from Underperform to Neutral and set a new price target of $18.00 from $12.00 previously
Robert W. Baird downgraded Assoc Banc-Corp from Outperform to Neutral and set a new price target of $27.00
Argus upgraded Teva Pharma from Hold to Buy and set a new price target of $20.00
SC 13G/A - Bioventus Inc. (0001665988) (Subject)
SC 13G/A - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Subject)
SC 13G/A - Clene Inc. (0001822791) (Subject)
TaskUs, Inc. (NASDAQ:TASK), a leading provider of outsourced digital services and next-generation customer experience to the world's most innovative companies, today announced its results for the second quarter ended June 30, 2024. Total revenues of $237.9 million. GAAP net income of $12.6 million, GAAP net income margin of 5.3%. Non-GAAP Adjusted Net Income of $28.6 million, non-GAAP Adjusted Net Income margin of 12.0%. GAAP diluted EPS of $0.14, non-GAAP Adjusted EPS of $0.31. Adjusted EBITDA of $51.3 million, Adjusted EBITDA margin of 21.5%. Net cash provided by operating activities of $30.0 million, Free Cash Flow of $25.5 million and 49.8% conversion of Adjusted EBITD
Alibaba Group Holding Limited (NYSE: BABA and HKEX: 9988 (HKD Counter) and 89988 (RMB Counter), "Alibaba" or "Alibaba Group") today announced that it will report its unaudited financial results for the quarter ended June 30, 2024 before the U.S. market opens on Thursday, August 15, 2024, and will hold a conference call to discuss the financial results at 7:30 a.m. U.S. Eastern Time (7:30 p.m. Hong Kong Time) the same day. All participants must pre-register to join this conference call using the Participant Registration link below: English: https://s1.c-conf.com/diamondpass/10040376-uTdhw.html Chinese: https://s1.c-conf.com/diamondpass/10040377-puyhg.html Upon registration, each partici
For an accessible version of this Press Release, please visit www.tevapharm.com Q2 2024 revenues of $4.2 billion reflecting an increase of 7% in U.S. dollars or 11% in local currency terms compared to Q2 2023.Generics business grows across all regions – increased in local currency terms by 16% in the U.S., 8% in Europe and 22% in International Markets, compared to Q2 2023.AUSTEDO – continued growth, U.S. revenue of $407 million in Q2 2024, an increase of 32% compared to Q2 2023; raising 2024 revenue outlook to ~$1.6 billion.AJOVY® – global revenues of $115 million in Q2 2024, an increase of 12% in local currency terms compared to Q2 2023.Announced acceleration of developme
TaskUs, Inc. (NASDAQ:TASK), a leading provider of outsourced digital services and next-generation customer experience to the world's most innovative companies today presents an Everest Group report revealing businesses are making significant investments in technology to streamline the customer experience (CX). AI Integration on Rapid Rise According to report data, more than 75% of enterprises are deploying or planning to deploy generative artificial intelligence (Gen AI) in various functions, including operations and customer services. These investments often take the form of Gen AI pilot programs to enhance agent-assist capabilities, improve content creation, enrich knowledge bases, anal
SALT LAKE CITY, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ:CLNN) (along with its subsidiaries, "Clene") and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), announced today that it will meet in-person with the U.S. Food and Drug Administration (FDA) before the end of November 2024 to discuss CNM-Au8 development for ALS. The meeting will include the FDA's Director of the Office on New Drugs, the Director of the Office of Neuroscience, and the Di
TEL AVIV, Israel, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will present at the Bank of America 2024 Global Healthcare Conference on Thursday, September 19, 2024. The presentation will begin at 8.15 A.M. British summer time (3.15 A.M. Eastern Time). To access a live webcast of the presentation, visit Teva's Investor Relations website at https://ir.tevapharm.com/Events-and-Presentations. An archived version of the webcast will be available within 24 hours after the end of the live discussion. About Teva Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a
4 - TaskUs, Inc. (0001829864) (Issuer)
4 - TaskUs, Inc. (0001829864) (Issuer)
4 - TaskUs, Inc. (0001829864) (Issuer)